Acadia Pharmaceuticals is my first Trump stock pick
The big test for Acadia Pharmaceuticals (ACAD) this quarter certainly wasn’t earnings. As an early stage biotech losses are expected and that’s exactly what the company delivered when it reported third quarter results on November 7. The loss came to 61...
Bristol-Myers continues to make up lost ground after August failure of Opdivo trial
Back on August 8 Bristol-Myers Squibb (BMY) announced that its key immuno-oncology drug Opdivo had failed to demonstrate its efficacy in a trial for treating lung cancer. At the time I characterized this particular trial as a part of a go-for-broke strategy that would...
Abbott Labs acquisition candidate St. Jude has a battery problem
Back on September 20 I questioned whether management at Abbott Laboratories had the skills to execute a growth through acquisitions strategy. At the time the company was–and it still is–involved in a dispute with Allere (ALR) over whether that company had...
Two acquisitions in a day: What is Allergan up to?
Update September 23, 2016 Allergan (AGN), which I added to my Jubak’s Picks portfolio on July 30, 2015 on the strength of its Botox franchise, acquired two companies on September 20. Neither is in the Botox or cosmetic drugs space. Both, in fact, are companies...
Bristol-Myers gambled and lost on a quick expansion of cancer drug Opdivo’s market–but there’s still good upside in the shares
Update September 21. Let’s be clear about what happened to Bristol-Myers Squibb (BMY) and its key immuno-oncology drug Opdivo on Friday, August 8, when the company announced that Opdivo had failed to demonstrate its efficacy in a trial for treating lung cancer....
Abbott looks to acquire its way out of a growth slump
Where do you find growth in a low-growth economy? If Wall Street projections are correct, the about-to-close third quarter of 2016 will show a 2% year-over-year drop in earnings for the Standard & Poor’s 500 companies–the sixth consecutive quarterly...Update Teva Pharmaceuticals (TEVA)
All it took on December 9 to pop shares of Teva Pharmaceutical Industries (TEVA) was good news on the Phase III study on oral laquinimod for multiple sclerosis. The two-year study found that patients experienced a statistically significant reduction in relapse rate...Buy Abbott Laboratories (ABT)
At current prices I think you’re getting two of Abbott Laboratories (ABT) most interesting growth opportunities at a deep discount. Abbott is a good mainstream pharmaceutical company. Abbott’s blockbuster drugs include Humira (for rheumatoid and psoriatic arthritis:...Update Teva Pharmaceutical Industries (TEVA)
It’s great earnings for the second quarter (announced on July 27) versus long-term worries for Teva Pharmaceutical Industries (TEVA) right now. With an assist from sell on the good news, long-term worries are winning at the moment. For the second quarter earnings...Update Teva Pharmaceutical Industries (TEVA)
Shares of Teva Pharmaceutical Industries (TEVA) plunged almost 8.6% on Friday on news that a competitor Momenta Pharma (MNTA) had beaten Teva and would be the first company to get U.S. Food and Drug Administration approval for a generic version of Sanofi Aventis’...In the drug sector go where the growth is: generics and emerging economies
If you can‘t beat ‘em, join ‘em. After years of worry that generic drug makers were going to destroy the profits of big U.S. drug makers, Big Pharma has figured out a solution: Buy them. Especially if the generic maker has big market share in a rapidly growing market...Update Teva Pharmaceutical (TEVA)
Today (March 18) Teva Pharmaceutical Industries (TEVA) announced an agreement to buy Germany’s Ratiopharm for $5 billion in cash. Privately-owned Ratiopharm is Germany’s second largest maker of generic medicines—and the sixth largest generic drug company in the world....Buy Teva Pharmaceutical (TEVA)
No matter exactly what health care reform bill (even no bill) emerges from Congress this year, the pressure to get costs out of the healthcare system is just going to get more intense. (For why see my October 13 post,...Here we go again: Drug stocks rally but is that a reaction to merger news or a sign that investors are getting more defensive?
Last time we had a one day pull back that led some of us (okay, me) to question whether this rally was getting tired we saw the stock market as a whole go down but the drug sector move up. Now today’s strength in the sector on a down day for the market as a...Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!